H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Protalix (PLX) to $12 from $15 and keeps a Buy rating on the shares following the Q3 report. The firm cites a more gradual ramp in Elfabrio sales and associated royalties for the target drop.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLX: